Clinical Trials Browser

Phase 2 × Ferrosoferric Oxide × Clear all

NCT03270059 2026-02-27

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Phase 2 Recruiting

Brain Neoplasms, Cranial Nerve Diseases, Central Nervous System Neoplasms

NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2 Terminated

52 enrolled 15 charts

Glioblastoma

NCT01336803 2023-12-27

Osteosarcoma

Phase 2 Completed

32 enrolled 11 charts

Bone Neoplasms, Chondrosarcoma, Osteomyelitis, Osteonecrosis, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT00659126 2023-09-07

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Phase 2 Terminated

40 enrolled 8 charts

Brain Neoplasms

NCT03325166 2022-08-10

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Terminated

2 enrolled 8 charts

Lung Carcinoma Metastatic in the Brain

NCT02141490 2019-09-06

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Phase 2 Completed

43 enrolled 12 charts

Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms